CEL-SCI (CVM): Projected Price to Earnings
A dedicated team of veteran scientists established the foundation of CEL-SCI Corporation (CVM). The company's expected P/E trend reflects current market dynamics, where 0.00 represents the latest level. Prospects depend on the success of Multikine and FDA decisions, as well as the implementation of eco-friendly chemical waste recycling systems within the laboratories.
Metric breakdowns and analytics for CEL-SCI Corporation (CVM)
- stock quotes and analyst forecast:
- stock exchange capitalization data:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Capital CEL-SCI Corporation|CVM - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital CEL-SCI Corporation|CVM - Company Cumulative Debt|Debt to Book Capitalization Ratio CEL-SCI Corporation|CVM - Company Long-Term Debt|Company Current Liabilities CEL-SCI|Quick Liquidity cel-sci.com
- company profitability and valuation multiples indicators:
CVM - Net Financial Result|Projected Future Earnings CEL-SCI Corporation|CVM - Price to Earnings Ratio|Forward P/E Multiple CEL-SCI Corp|CVM - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio CEL-SCI|CVM - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) CEL-SCI|CVM - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months cel-sci.com|CVM - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year CEL-SCI Corporation
- sales volume and revenue information:
Analysis of all company metrics:CVM CEL-SCI Corp
CEL-SCI Corporation operations are constrained by a critical shortage of funds and capital dilution risks, making the company's 12-month forward P/E analysis a key tool for assessing business viability. This indicator compares the issuer's current market value with projected net income, allowing investors to determine the extent of the asset's overvaluation amid the uncertainty of clinical approvals.
Competing companies
Forward P/E Multiple ONC|HALO (Halozyme Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (revmed.com)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Bio (BCAX) - Future Price to Earnings|Personalis Corp - Future Price to Earnings Multiple|ERAS (Erasca Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Systems, Inc. DCTH|Projected Price to Earnings YMAB (Y-mAbs Corp)|Forward P/E Multiple Aura Bio (AURA)|Forward P/E Multiple CADL (Candel Therapeutics Inc.)|ARAY - Projected Price to Earnings|SLS - Future Price to Earnings|Actuate Therapeutics - Market Cap to Future Earnings Ratio|CTOR: Forward P/E Multiple|TuHURA (HURA) - Forward P/E Multiple|TARA (Protara Therapeutics Inc) - Forward P/E Multiple|FATE: Future Price to Earnings Multiple|Forward P/E Multiple WHWK|TCRX (TScan) - Future Price to Earnings Multiple|Future Price to Earnings Champions Oncology, Inc. CSBR|XBIT - Projected Price to Earnings|OS Therapies Inc. - Forward P/E Multiple|RADX - Forward P/E Multiple|ARTV: Forward P/E Multiple|ANL: Market Cap to Future Earnings Ratio|Projected Price to Earnings VERU|TPST: Future Price to Earnings Multiple|Future Price to Earnings xiliotx.com (XLO)|Renovaro - Price to Future Earnings Ratio|Future Price to Earnings Mural Oncology MURA|KAPA - Projected Price to Earnings|OKUR - Future Price to Earnings|GDTC - Forward P/E Multiple|Curis, Inc. (CRIS) - Future Price to Earnings|Projected Price to Earnings Apollomics, Inc.|Projected Price to Earnings THAR|Price to Future Earnings Ratio ADVB (Advanced Biomed)|Projected Price to Earnings GNPX (Genprex, Inc)|CLDI: Price to Expected Earnings Ratio|Future Price to Earnings sunshinebiopharma.com SBFM|XBIO - Projected Price to Earnings|SLRX: Projected Price to Earnings|Purple Biotech - Market Cap to Future Earnings Ratio|American Oncology Network (AONC) - Future Price to Earnings|Price to Future Earnings Ratio BGNE|Projected Price to Earnings CKPT|Future Price to Earnings ELEV|Forward P/E Multiple ICAD|Forward P/E Multiple Ikena Oncology Inc. (IKNA)|Forward P/E Multiple NTBL (Notable Labs Ltd)|Market Cap to Projected Earnings Viracta Therapeutics (VIRX)|MOR: Projected Price to Earnings|NAYA (NAYA Bio) - Price to Future Earnings Ratio|AAPGV: Forward P/E Multiple
